2.Application of peer-assisted learning based on Mini-CEX combined with DOPS evaluation in the teaching of autoimmune liver diseases.
Yansheng LIU ; Jiangyi ZHU ; Yulong SHANG ; Ying HAN
Chinese Journal of Cellular and Molecular Immunology 2024;40(12):1146-1150
Objective To explore the effects of peer assistance model based on mini-clinical evaluation exercise (Mini-CEX) combined with direct observation of procedural skill (DOPS) in the teaching of autoimmune liver diseases (AILDs). Methods A total of 115 residents receiving training in the Department of Gastroenterology of Xijing Hospital were selected and divided into a control group and an experimental group according to the order in which they came to the department. The control group received traditional teaching mode, while the experimental group underwent peer assistance model based on Mini-CEX combined with DOPS. Results The experimental group showed significantly higher scores in both clinical competence and medical record documentation compared to the control group. In addition, the experimental group reported higher satisfaction levels in terms of self-learning ability, learning interest, communication skills and cooperation ability. The overall satisfaction of the experimental group is higher than that of the control group. Conclusion The use of peer assisted learning mode based on Mini-CEX and DOPS in the AILD teaching could improve the teaching effects.
Humans
;
Autoimmune Diseases/therapy*
;
Liver Diseases/therapy*
;
Male
;
Female
;
Peer Group
;
Clinical Competence
;
Adult
;
Teaching
;
Learning
3.Anti-HMGCR immune-mediated necrotizing myopathy: A case report.
Yuan Jin ZHANG ; Jing Yue MA ; Xiang Yi LIU ; Dan Feng ZHENG ; Ying Shuang ZHANG ; Xiao Gang LI ; Dong Sheng FAN
Journal of Peking University(Health Sciences) 2023;55(3):558-562
The patient was a 55-year-old man who was admitted to hospital with "progressive myalgia and weakness for 4 months, and exacerbated for 1 month". Four months ago, he presented with persistent shoulder girdle myalgia and elevated creatine kinase (CK) at routine physical examination, which fluctuated from 1 271 to 2 963 U/L after discontinuation of statin treatment. Progressive myalgia and weakness worsened seriously to breath-holding and profuse sweating 1 month ago. The patient was post-operative for renal cancer, had previous diabetes mellitus and coronary artery disease medical history, had a stent implanted by percutaneous coronary intervention and was on long-term medication with aspirin, atorvastatin and metoprolol. Neurological examination showed pressure pain in the scapularis and pelvic girdle muscles, and V- grade muscle strength in the proximal extremities. Strongly positive of anti-HMGCR antibody was detected. Muscle magnetic resonance imaging (MRI) T2-weighted image and short time inversion recovery sequences (STIR) showed high signals in the right vastus lateralis and semimembranosus muscles. There was a small amount of myofibrillar degeneration and necrosis, CD4 positive inflammatory cells around the vessels and among myofibrils, MHC-Ⅰ infiltration, and multifocal lamellar deposition of C5b9 in non-necrotic myofibrils of the right quadriceps muscle pathological manifestation. According to the clinical manifestation, imageological change, increased CK, blood specific anti-HMGCR antibody and biopsy pathological immune-mediated evidence, the diagnosis of anti-HMGCR immune-mediated necrotizing myopathy was unequivocal. Methylprednisolone was administrated as 48 mg daily orally, and was reduced to medication discontinuation gradually. The patient's complaint of myalgia and breathlessness completely disappeared after 2 weeks, the weakness relief with no residual clinical symptoms 2 months later. Follow-up to date, there was no myalgia or weakness with slightly increasing CK rechecked. The case was a classical anti-HMGCR-IMNM without swallowing difficulties, joint symptoms, rash, lung symptoms, gastrointestinal symptoms, heart failure and Raynaud's phenomenon. The other clinical characters of the disease included CK as mean levels >10 times of upper limit of normal, active myogenic damage in electromyography, predominant edema and steatosis of gluteus and external rotator groups in T2WI and/or STIR at advanced disease phase except axial muscles. The symptoms may occasionally improve with discontinuation of statins, but glucocorticoids are usually required, and other treatments include a variety of immunosuppressive therapies such as methotrexate, rituximab and intravenous gammaglobulin.
Male
;
Humans
;
Middle Aged
;
Autoantibodies
;
Myositis/diagnosis*
;
Autoimmune Diseases
;
Muscle, Skeletal/pathology*
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use*
;
Necrosis/pathology*
;
Muscular Diseases/drug therapy*
4.A review of the clinical progress on helminths and their derivative products in autoimmune disease.
Xinyue WU ; Hongyu GAO ; Shuyao DUAN ; Wenbo DING ; Xiaodi YANG
Chinese Journal of Cellular and Molecular Immunology 2023;39(12):1132-1140
Traditional medications used for treating autoimmune diseases often come with a wide range of adverse effects. Current treatments focus mainly on symptom management, resulting in significant health issues and financial burdens for patients. Recently, clinical research has demonstrated the potential of helminths and their derivatives as effective therapies for autoimmune disorders. Helminths, being a near-natural immunomodulator, exhibit milder effects than broad-spectrum immunosuppressants and corticosteroids, thereby presenting a promising alternative for the treatment of autoimmune diseases. However, different helminths' therapeutic efficacy and mechanisms and their derivatives in treating autoimmune diseases may vary. Therefore, we aim to review recent clinical advancements in the use of helminths and their derivatives for treating inflammatory bowel disease, multiple sclerosis, and autism spectrum disorder, with a view to offering novel clinical treatment approaches.
Animals
;
Humans
;
Autism Spectrum Disorder
;
Autoimmune Diseases/drug therapy*
;
Helminths
;
Inflammatory Bowel Diseases
5.Application and Effectiveness of Chinese Medicine in Regulating Immune Checkpoint Pathways.
Luo-Jie XIONG ; Yue-Feng TIAN ; Chun-Tao ZHAI ; Wei LI
Chinese journal of integrative medicine 2023;29(11):1045-1056
Immunotherapy targeting immune checkpoint molecules has emerged as a key approach in cancer treatment, representing the forefront of antitumor research. However, studies on immune checkpoint molecules have mainly focused on targeted therapies. Chinese medicine (CM) research as a complementary medicine has revealed that immune checkpoint molecules also undergo disease-specific changes in the context of autoimmune diseases. This review article presents a comprehensive analysis of CM studies on immune checkpoint molecules in the last 5 years, with a focus on their role in different diseases and treatment modalities. CM research predominantly utilizes oral administration of herbal plant extracts or acupuncture techniques, which stimulate the immune system by activating specific acupoints through temperature and needling. In this study, we analyzed the modulation and mechanisms of immune checkpoint molecules associated with different coinhibitory and costimulatory molecules, and reviewed the immune functions of related molecules and CM studies in treating autoimmune diseases and tumors. By summarizing the characteristics and research value of CM in regulating immune checkpoint molecules, this review aims to provide a useful reference for future studies in this field.
Humans
;
Medicine, Chinese Traditional/methods*
;
Immune Checkpoint Proteins
;
Acupuncture Therapy/methods*
;
Neoplasms/pathology*
;
Autoimmune Diseases
7.Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis.
Xiao LIANG ; Ya-Lan LI ; Hao-Tian BAI ; Qing-Yu ZHANG ; Zhan XIAO ; Xin SUN ; Wu-Long WEN ; Wei-Ye ZHANG ; Jing YANG ; Rui WANG
China Journal of Chinese Materia Medica 2023;48(18):4874-4883
Rheumatoid arthritis(RA) is a widely prevalent autoimmune inflammatory disease that severely affects patients' quality of life. Currently, conventional formulations against RA have several limitations, such as nonspecificity, poor efficacy, large drug dosages, frequent administration, and systemic side effects. Nanotechnology-based drug delivery systems have emerged as a promising stra-tegy for the diagnosis and treatment of RA since nanotechnology can overcome the limitations of traditional treatments and simplify the complexity of the disease. These systems enable targeted delivery of anti-inflammatory drugs to the inflamed areas through active and passive targeting, achieving specificity to the joints, overcoming the need for increased dosage and administration frequency, and reducing associated adverse reactions. This article aimed to review nanocarrier-based drug delivery systems in the field of RA and elucidate how nanosystems can be utilized to deliver therapeutic drugs to inflamed joints for controlling RA progression. By discussing the current issues and challenges faced by nanodrug delivery systems and highlighting the urgent need for solutions, this article offers theoretical support for further research on nanotechnology-based co-delivery systems in the future.
Humans
;
Quality of Life
;
Drug Delivery Systems
;
Arthritis, Rheumatoid/drug therapy*
;
Autoimmune Diseases/drug therapy*
;
Nanotechnology
8.Research progress in treatment of Sjögren's syndrome by traditional Chinese medicine.
Xia ZHANG ; Xiang-Yu LI ; Xiong-Wei ZHANG ; Nan ZENG
China Journal of Chinese Materia Medica 2023;48(12):3235-3245
Sj9gren's syndrome(SS) is an autoimmune disease with glandular dysfunction caused by the massive infiltration of the exocrine glands by lymphocytes. The pathogenesis of this disease is related to the chronic inflammatory response of the exocrine glands due to excessive activation of B cells and T cells. In addition to dry mouth and eyes, SS can also cause damage to other organs and systems in the human body, seriously affecting the quality of life of patients. Traditional Chinese medicine(TCM) has definite clinical efficacy in the treatment of SS as it can alleviate symptoms and regulate immune disorders without causing adverse reactions, demonstrating high safety. This paper reviews the current status of preclinical and clinical trials about the TCM treatment of SS in the past decade. TCM mainly mitigates SS symptoms such as dry mouth, dry eyes, dry skin, and joint pain and improves the prognosis and quality of life of patients by regulating the abnormally activated B cells and T cells, inhibiting the autoimmune response, restoring the balance between pro-inflammatory and anti-inflammatory cytokines, and reducing the pathological damage caused by immune complexes to exocrine glands and joints in SS patients.
Humans
;
Sjogren's Syndrome/drug therapy*
;
Medicine, Chinese Traditional
;
Quality of Life
;
Xerostomia
;
Autoimmune Diseases
9.Progress on the diagnosis and therapy about atopic diseases and primary immunodeficiency diseases.
Zhou Xian PAN ; Ying Yang XU ; Sai Nan BIAN ; Ji LI ; Yu Lin JIANG ; Ji LI ; Kai GUAN
Chinese Journal of Preventive Medicine 2022;56(9):1218-1225
Primary immunodeficiency diseases (PID) is a congenital disease caused by single gene germline mutation related to the immune system. PID patients have immune dysregulation, and are susceptible to infectious diseases, autoimmune diseases, autoimmune diseases, allergic diseases, and malignant tumors. The first symptom of some PID patients is atopic disease, therefore they go to the department of allergy, department of pediatrics and other relevant departments. How to identify and diagnose PID in allergic patients, to reduce diagnosis delay and prevent disease aggravation are the abilities that allergists, pediatricians, and doctors in other relevant departments need to master. This article summarizes the warning signs of PID in allergic patients and the mechanism of allergy combined with PID, and then summarizes the common types of PID in allergic patients, the evaluation, treatment and prevention in patients with PID and allergy.
Autoimmune Diseases
;
Child
;
Humans
;
Hypersensitivity/therapy*
;
Immunologic Deficiency Syndromes/therapy*
;
Primary Immunodeficiency Diseases/therapy*
10.Interpretation of 2021 French Guidelines for the Therapeutic Management of Bullous Pemphigoid.
Acta Academiae Medicinae Sinicae 2022;44(5):828-836
Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease.The diagnosis of BP relies on clinical manifestation,histopathology,direct and indirect immunofluorescence,and serological assay.In the past two decades,topical corticosteroids and systemic and/or topical corticosteroids were the major therapeutic options for localized/mild/moderate and extensive/severe BP,respectively.In 2021,several experts from the French Study Group on Autoimmune Bullous Skin Diseases collaboratively issued the updated guidelines for the therapeutic management of BP based on evidence-based medicine.The guidelines fully detailed the updated therapeutic options for extensive BP,BP of limited extent,localized form of BP,corticosteroid-dependent BP,and drug-induced/associated BP.In particular,systemic corticosteroids are no longer the first-line treatment for extensive BP.We interpret the guidelines to assist dermatologists in the comprehensive management of BP and promote the standardization of BP treatment.
Humans
;
Pemphigoid, Bullous/drug therapy*
;
Autoimmune Diseases/drug therapy*
;
Glucocorticoids/therapeutic use*
;
Adrenal Cortex Hormones/therapeutic use*

Result Analysis
Print
Save
E-mail